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A B S T R A C T
Adrenal glands removed for unilateral primary aldosteronism (PA) display marked histological hetero-
geneity. Recently reported somatic mutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D can partially account
for these differences. In this study we aimed at combining phenotypic and genotypic characteristics, in-
tegrating genetic and immunohistochemistry correlates in sporadic PA. Seventy-one adrenal glands have
been included in the study and analyzed for mutations in KCNJ5, ATP1A1, ATP2B3 and CACNA1D. His-
tological examination and immunohistochemical staining for CYP11B1 (11β-hydroxylase) and CYP11B2
(aldosterone synthase) were performed on aldosterone-producing adenomas (APAs) and adjacent adrenal
cortex. In our cohort, the final histopathological diagnosis was multinodular hyperplasia in 22.5% of the
patients and single nodule in 77.5%. Forty-five percent of the removed adrenals displayed extra-APA
CYP11B2-positive cell nests (B2-CN). Among adrenal vein sampling parameters the suppression of con-
tralateral adrenal was more frequent and the lateralization index was higher in the subgroup of patients
without extra-APA B2-CN compared to the subgroup with extra-APA B2-CN. KCNJ5-mutated APAs were
composed mainly of zona fasciculata-like cells with high expression of CYP11B1, while ATP1A1, ATP2B3
and CACNA1D-mutated APAs presented more frequently a zona-glomerulosa-like phenotype with high
expression of CYP11B2. We observed a significant inverse correlation between CYP11B2 expression and
the size of the nodules and, if CYP11B2 expression was corrected for tumor volume, a significant cor-
relation with plasma aldosterone and aldosterone to renin ratio. Our findings indicate that combination
of genotyping and immunohistochemistry improves the final histopathological diagnosis between single
nodule and multinodular hyperplasia of the assessed adrenals.
© 2015 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Primary aldosteronism (PA) is the most frequent cause of
endocrine hypertension (Funder et al., 2008) and affected patients
display an increased risk of cardio- and cerebro-vascular
complications compared with age-, sex- and BP-matched essential
hypertensives (Mulatero et al., 2013). Aldosterone producing
adenoma (APA) and bilateral adrenal hyperplasia (BAH) account for
the great majority of all PA cases (Mulatero et al., 2004). The
differential diagnosis between APA and BAH is of fundamental
importance to allocate affected patients to appropriate management:
either unilateral adrenalectomy for an APA or medical therapy with
mineralocorticoid receptor antagonists for BAH. Preoperative subtype
diagnosis is based on computed tomography (CT) scanning and
adrenal vein sampling (AVS), which is the only reliable approach
to distinguish between unilateral and bilateral disease (Funder et al.,
2008). CT scanning has been widely demonstrated to lack sensitivity
and specificity since micro-APAs (less than 1 cm in diameter) are
not always detectable and a non-secreting nodule in the context of
a bilateral hyperplasia may be misclassified as an APA (Funder et al.,
2008; Mulatero et al., 2008). Preoperative diagnosis of APA is usually
confirmed by the cure or significant amelioration of hypertension,
Abbreviations: PA, primary aldosteronism; APA, aldosterone producing adenoma;
BAH, bilateral adrenal hyperplasia; AVS, adrenal vein sampling.
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normalization of hypokalemia and aldosterone–renin ratio (ARR)
and also by the histological examination of the adrenal that
frequently reveals macro- and microscopic heterogeneities. Most
adrenals with an APA comprise a single well-circumscribed nodule,
although frequently the removed gland displays macro- or
micronodular hyperplasia (Dekkers et al., 2014), with various
degrees of adrenal cortex remodeling, that is atrophic, with diffuse
hyperplasia or nodular hyperplasia (Boulkroun et al., 2010).
In the adult adrenal gland the exclusive site of aldosterone pro-
duction is the zona glomerulosa, the localization of CYP11B2 gene
expression that encodes the rate-limiting enzyme of aldosterone
production, aldosterone synthase. However, the most common APAs
are composed mainly of zona fasciculata (ZF)-like cells (large clear
cells with lipid-laden cytoplasm and small nuclei). Less frequent are
APA comprising zona glomerulosa (ZG)-like cells (small, with a high
nuclear–cytoplasmic ratio and a smaller lipid content compared to
ZF-like cells) or hybrid cells (intermediate between ZF-like and ZG-
like cells) (Neville and O’Hare, 1985). Histopathological differences
in cellular composition have been proposed to account for the dif-
ferent aldosterone responses to angiotensin II (AII) in APAs (Tunny
et al., 1991): tumors predominantly fasciculata-like (≥50%) have been
reported to be mostly AII-unresponsive (AII-U), in contrast, AII-
responsive (AII-R) APAs contain less than 20% of ZF-like cells (Tunny
et al., 1991). Immunohistochemical analyses of the steroidogenic
enzymes aldosterone synthase (CYP11B2) and 11β-hydroxylase
(CYP11B1, which catalyzes the terminal step of cortisol synthesis)
provide important functional information and help the histopatho-
logical diagnosis of PA. Adrenal nodules and the adjacent adrenal
cortex display varied distributions of 11β-hydroxylase and various
degrees of aldosterone synthase expression, including cell clus-
ters that exhibit strong CYP11B2 immunostaining despite the
suppressed renin–angiotensin system, called aldosterone produc-
ing cell clusters (APCCs), whose functional significance has not been
fully elucidated (Dekkers et al., 2014; Nishimoto et al., 2010).
Identification of somatic mutations in genes involved in Ca2+ ho-
meostasis (KCNJ5, ATP1A1, ATP2B3 and CACNA1D) in almost 55–
70% of sporadic APAs has represented a major advance in our
understanding of the pathogenesis of PA (Monticone et al., 2014a).
Clinical and biochemical correlates of somatic mutations in APAs
revealed that KCNJ5 mutations were significantly more prevalent
in females than in males and in young patients (Boulkroun et al.,
2012; Fernandes-Rosa et al., 2014) with large adenomas (Azizan et al.,
2013), whereas CACNA1D mutations were frequently identified in
small adenomas (Fernandes-Rosa et al., 2014).
In this study we exploited the recently developed monoclonal
antibodies against 11β-hydroxylase and aldosterone synthase
(Gomez-Sanchez et al., 2014) to integrate clinical, immunohisto-
chemical and genetic correlates in a cohort of 71 adrenal glands
removed following the diagnosis of unilateral PA.
2. Materials and methods
2.1. Patients selection
Adrenal glands included in the study were removed from pa-
tients affected by unilateral PA, diagnosed in two tertiary referral
hypertension centers (Division of Internal Medicine 4 – Hyperten-
sionUnit andDivision of Endocrinology), at the University of Torino,
Italy. Case detection and subtype differentiationwere performed ac-
cording to the Endocrine Society Guidelines (Funder et al., 2008) as
described previously (Monticone et al., 2014b). Briefly, after with-
drawal of interferingmedications, aldosterone toplasma reninactivity
ratio (ARR) was used as a screening test for PA. The diagnosis was
confirmedwith i.v. saline loading test or captopril challenge test (when
acute plasma volume expansion was contraindicated) and patients
with confirmed PA underwent adrenal CT scanning and adrenal vein
sampling (AVS). Two patients underwent adrenalectomy without
AVS: in one case adrenal CT scanning revealed a single nodule greater
than 4 cm, suspicious for adrenocortical carcinoma and in the other
case the patients refused the procedure andwas considered to have
“high probability of APA” (Young et al., 2004). In two cases AVSwas
not successful and the patients underwent unilateral adrenalec-
tomy on the basis of positive adrenal CT findings and clinical
parameters. AVS procedures were performed as described previ-
ously (Monticone et al., 2012); AVSwas considered to be successful
if the cortisoladrenal vein/cortisolperipheral vein was >3 (>2 before 2008) and
to show lateralization when the aldosterone/cortisoladrenal vein/
aldosterone/cortisolcontralateral adrenal vein was >4 or if it was >3 together
with contralateral suppression (aldosterone/cortisol in the contra-
lateral vein lower than that in the peripheral vein). All patients
showing lateralization at the AVS underwent unilateral laparo-
scopic adrenalectomy. Resected adrenals were assessed
macroscopically andmicroscopically. The diagnosis of unilateral PA
was confirmed by cure or significant amelioration of hypertension,
normokalemia, normal ARR and low aldosterone levels and/or the
normal suppressibility of aldosterone (follow up data available for
69/71 patients). The posture test (available for 51 patients) was per-
formedbymeasuringplasmaaldosteroneat08:00 hafter recumbency
and after 2 h of standing; a greater than 50% increase in plasma al-
dosterone levels over basal was considered a positive test result. All
patients displaying at adrenal CT scanning a nodule greater than
1 cm underwent 1 mg-overnight dexamethasone suppression test
to exclude subclinical hypercortisolism. The testwas considered pos-
itivewhen plasma cortisol failed to suppress to less than 50 nmol/L
(Fallo et al., 2011). All patients gave their written informed consent
for the use of the samples and the clinical data and the protocol of
the study was approved by our local ethics committee.
2.2. DNA sequencing of KCNJ5, ATP1A1, ATP2B3 and CACNA1D
DNA fragments from KCNJ5, ATP1A1, ATP2B3 and CACNA1D were
PCR amplified using primers reported previously (Fernandes-Rosa
et al., 2014; Williams et al., 2014). The validity of novel mutations
was confirmed by sequencing both strands of an independently am-
plified PCR fragment. The present cohort of 71 APA samples (55 from
the Division of Internal Medicine and Hypertension and 16 from
the Division of Endocrinology) were all included in the study by
Fernandes-Rosa et al. (2014). Hot spot regions formutations in KCNJ5,
ATP1A1, ATP2B3 and CACNA1D were sequenced in all 71 APAs in-
cluded in the study. The overall prevalence of somatic mutations
was 51% (36/71) with 38% (27/71) of KCNJ5 mutations, 8.5% (6/71)
of ATPase mutations (5 ATP1A1 mutations and 1 ATP2B3 muta-
tion) and 4.2% (3/71) of CACNA1Dmutations. Clinical and biochemical
data of the patients included in the study, before and after adre-
nalectomy, according to the mutational status are summarized in
Supplementary Table S1.
2.3. Pathological analysis
Histological examination was performed by an experienced pa-
thologist (I.C.) on APAs and adjacent adrenal cortex. All adrenal glands
included in the study were paraffin embedded, cut into 3 μm thick
slices and stained with H&E. The diagnosis of single nodule was con-
sidered when only one tumor was present; the diagnosis of
multinodular hyperplasia was considered when several nodules of
different sizes could be seen (with or without a dominant nodule).
Cellular composition was determined by examining for known fea-
tures of zona fasciculata (large, lipid-laden clear cells, with round
to oval vesicular nuclei), zona glomerulosa (small, compact cells,
with high nuclear/cytoplasmic ratio and moderate amount of lipid)
and zona reticularis (lipid-sparse cytoplasm, compact cells) cells
(Nakamura et al., 2014; Neville and O’Hare, 1985). The tumors were
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classified as ZF-like when the percentage of large vacuolated cells
was greater than 50%, and ZG-type when the percentage of ZF-
like cells was <50% and ZG-type cells were the most prominent cell
type. The adrenal cortex adjacent to a nodule was examined for the
presence of extra-APA CYP11B2-positive cell nest (B2-CN) (in two
samples no adjacent adrenal cortex was available for microscopic
examination), defined as cell clusters showing CYP11B2 but not
CYP11B1 immunohistochemical expression (Dekkers et al., 2014;
Nishimoto et al., 2010). Assuming the tumor shape as a sphere, the
tumor volume was estimated using the formula: volume = 4/3πr3,
where “r” represents the radius of the nodule measured by micro-
scopical evaluation.
2.4. Immunohistochemical and immunofluorescence procedure
Immunohistochemistry was performed using the following
primary antibodies: rat monoclonal anti-human CYP11B1-80-7 (11β-
hydroxylase) and mouse monoclonal anti-human CYP11B2-41-17
(aldosterone synthase) (Gomez-Sanchez et al., 2014). For both pro-
tocols, sections of 3 μm thickness from paraffin-embedded adrenal
tissue were incubated with H2O2, and pre-treated with EDTA 0.1mM
(pH 8) for 40 minutes at 98 °C for antigen retrieval. Subsequently,
to detect CYP11B1 expression, after endogenous biotin blocking by
sequential avidin–biotin treatment, the slides were incubated over-
night at 4 °C with the primary antibody diluted 1:100. After rinsing
in PBS, slides were treatedwith biotinylated secondary antibody goat
anti-rat (STARD131, AbD Serotec, diluted 1:300) for 30 minutes, fol-
lowed by the incubation with Streptavidin-HRP (Millipore) for 15
minutes. To detect aldosterone synthase, after antigen retrieval, slides
were incubated with anti-CYP11B2 (1:1000) over-night at 4 °C. After
rinsing in PBS, the EnVision reagent (Dako, Carpinteria, CA) coupled
with peroxidase-labeled polymer was incubated as secondary an-
tibody for 30 min. The proteins were visualized with 3,3′-
diaminobenzidine tetrahydrochloride and counterstained with
hematoxylin. Immunoreactivity for CYP11B2 was assessed
semiquantitatively by the McCarthy H-score, with all tumors ex-
amined under a 20× objective. In each field the percentage of
immunopositive cells was assessed and then multiplied by a factor
(1–3) according to the intensity of the immunopositivity (1 = weak;
2 = intermediate; 3 = strong) (McCarty et al., 1985).
Immunofluorescence was performed as previously described
(Gomez-Sanchez et al., 2014).
2.5. Statistical analysis
IBM SPSS statistics 21 was used for the statistical analyses. All
data are presented as mean ± SD or 25th to 75th percentile. Data
were analyzed by the Kolmogorov–Smirnov and Shapiro–Wilk tests
to determine their distribution. Statistically significance between
groups was calculated in normally distributed data by Student’s t
test for independent samples or ANOVA, in non-normally distrib-
uted data by Kruskal–Wallis and Mann–Whitney U test. The chi-
square test or the Fisher exact test was applied for qualitative
variables. Correlations were evaluated by Pearson correlation anal-
ysis and Spearman’s rank-order tests. A probability value of P ≤ 0.05
was considered statistically significant.
3. Results
3.1. Macroscopic evaluation
We assessed macroscopically 71 adrenals removed from pa-
tients affected by unilateral PA. On the basis of adrenal CT scanning,
56 patients showed a single nodule, 4 multiple nodules and in 11
patients adrenal CT scanning could not identify any adrenal mass.
Of the 11 patients in whom adrenal CT scanning did not show any
nodule, the final diagnosis at histopathological examination was
single nodule in 4 patients and multinodular hyperplasia in 7 pa-
tients. Notably, 2 of the 11 patients without nodules on imaging had
a CACNA1D mutation in agreement with previous reports that pa-
tients with CACNA1D mutations had smaller adenomas than those
with KCNJ5mutations or no mutations (Fernandes-Rosa et al., 2014;
Azizan et al., 2013). Overall, the final histopathological diagnosis
was single nodule in 55 adrenals and multinodular hyperplasia in
16 adrenals. Interestingly, the final diagnosis of single nodule was
more frequent in female than inmale patients (F = 32; M = 23), while
the multinodular hyperplasia appeared more common in males
(F = 7; M = 9). Despite the different sex distribution, the preva-
lence of KCNJ5 mutations did not differ between the two groups:
single nodule 21/55, multinodular hyperplasia 6/16.
3.2. Microscopic evaluation
Analysis of histological features according to mutational status
was performed in all 71 adrenal gland samples. Overall, 61% (43/
71) APAs removed consisted mainly (≥50%) of ZF-like cells (Fig. 1,
panel A), while 39% (28/71) were mainly ZG-like cells (Fig. 1, panel
B). Analysis of cellular composition according to themutational status
revealed that KCNJ5-mutated APAs were composed mainly of ZF-
like cells compared with both wild-type and CACNA1D mutated
tumors (both P < 0.001). All the three APAs carrying mutations in
CACNA1D were composed mainly of ZG-like cells. Of note, in our
series of APAs, we could not identify any relationship between the
cellular composition of the tumors and the responsiveness of al-
dosterone to upright posture.
Clinical and biochemical correlates according to cellular com-
position are summarized in Table 1. We observed that adrenal
nodules composed mainly of ZF-like cells display higher preva-
lence of KCNJ5 mutation, higher prevalence of CYP11B1 expression
and lower CYP11B2 expression than ZG-like nodules (as will be
further detailed later).
In addition, we examined the non tumor adrenal cortex from the
adrenal glands included in the study: 31 of the 69 available cases
(45%) contained extra-APA B2-CNs (Supplementary Fig. S1, panels
A and B). Patients’ characteristics, histopathology and immunohis-
tochemistry of adrenals with or without extra-APA B2-CNs are shown
in Table 2. Interestingly, patients without extra-APA B2-CNs dis-
played more frequently single nodules at adrenal CT scanning
compared to patients with extra-APA B2-CNs (Table 2). Moreover,
among AVS parameters, the suppression of the contralateral adrenal
was significantly more frequent (p = 0.039) and the LI was higher
(p = 0.018) in the subgroup without extra-APA B2-CNs compared
to the subgroup with extra-APA B2-CNs.
3.3. Immunohistochemical and immunofluorescence analysis
The final steps in mineralocorticoid and glucocorticoid biosyn-
thesis are catalyzed by two closely related mitochondrial enzymes:
11β-hydroxylase (encoded by CYP11B1 gene) and aldosterone syn-
thase (encoded by CYP11B2 gene) (Gomez-Sanchez et al., 2014).
Seventy-one adrenal glands removed for unilateral PA were
immunohistochemically examined for 11β-hydroxylase and aldo-
sterone synthase expression.
Sixty-nine major adrenal nodules were identified by macroscop-
ic examination: immunolocalization of steroidogenic enzymes
revealed that 61/69 (88%) of the nodules showed a variable degree
of CYP11B2 expression (median H-score 60, 25th–75th percentile
15–160). Adrenal nodules showing high expression of CYP11B2 (ar-
bitrarily defined as H-score >160, representing the 75th percentile)
were smaller, composed mainly of ZG-like cells (Fig. 1, panels C and
D) and with a higher prevalence of ATP1A1/ATP2B3 and CACNA1D
mutations compared to adrenal nodules with a lower score
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(H-score <160, Table 3). Moreover, we observed a significant inverse
correlation between CYP11B2 expression (H-score) and nodule size
(−0.308, p-value = 0.009). In addition, if CYP11B2 expression was cor-
rected for tumor volume, we observed a significant positive
correlation with plasma aldosterone and ARR. Two adrenals with
a final diagnosis of multinodular hyperplasia showed negative
immunostaining for CYP11B2 in the main nodule, but the enzyme
was expressed in a different smaller nodule (Supplementary Fig. S1,
panels C and D). Of the eight samples not expressing CYP11B2 (H-
score = 0), one case underwent adrenalectomy without AVS for
suspicion of aldosterone-producing adrenocortical carcinoma (hy-
peraldosteronism and hypertension were cured by adrenalectomy).
Overall, of the 8 patients showing negative CYP11B2 immunostaining,
7 expressed CYP11B1 in the main nodule, 2 had extra-APA B2-CNs
in the adjacent adrenal cortex, 6 were composed mainly of ZF-like
cells, 4 had a final diagnosis of adenoma, 4 of multinodular hyper-
plasia. Genotyping revealed that 5/8 were wild-type and 3/8 had
a mutation in KCNJ5. Overall, clinical and biochemical parameters
of patients expressing or not aldosterone synthase did not differ sig-
nificantly from each other (as detailed in Supplementary Tables S2
and S3).
H-score of CYP11B2 expression was significantly lower in adrenal
nodules expressing CYP11B1 compared to APAs not expressing
CYP11B1 (155 [45–262] vs 40 [10–120], p = 0.001) (Table 4) and the
Fig. 1. Examples of histopathological findings in adrenal glands of patients with unilateral PA. Panel A: Hematoxylin–eosin staining of a KCNJ5-mutated APA with prevalent
ZF-like cells; panel B: Hematoxylin–eosin staining of a CACNA1D-mutated APA composed mainly ZG-like cells; panel C: CYP11B2 immunostaining of an APA with prevalent
ZG-like cells; panel D: CYP11B2 immunostaining of an APA with prevalent ZG-like cells; panel E: CYP11B2 immunostaining of an APA with prevalent ZF-like cells; panel F:
CYP11B1 immunostaining of an APA with prevalent ZF-like cells.
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Table 1
Clinical and biochemical parameters of patients included in the study, immunohistochemistry and genotyping accord-
ing to the cellular composition.
Parameter Cellular composition P value
ZF-like
(n = 43)
ZG-like
(n = 28)
Age (years) 46 ± 11 49 ± 12 0.4
Sex (M/F) 18/25 14/14 0.6
SBP (mmHg) 170 ± 26 175 ± 27 0.5
DBP (mmHg) 105 ± 12 105 ± 14 0.9
Plasma K+ (mEq/L) 2.9 ± 0.8 2.9 ± 0.6 0.7
PRA (ng/mL/h) 0.2 [0.2–0.3] 0.2 [0.2–0.3] 0.3
Plasma aldosterone (ng/dL) 45.1[33.7–60.0] 49.3[38.2–67.2] 0.4
Adenoma size (mm) 1.8 ± 0.8 1.5 ± 1.1 0.2
Adrenal CT scanning 0.2
Single nodule, n (%) 34 (79%) 22 (79%)
Multiple nodules, n (%) 4 (9%) 0 (0%)
No nodules, n (%) 5 (12%) 6 (21%)
Lateralization index 9.3 [5.0–12.9] 9.3[4.5–19.4] 0.8
Contralateral suppression (yes/no) 32/9 21/5 1.0
Final diagnosis
Single nodule, n (%) 33 (77%) 22 (79%) 0.5
Multinodular hyperplasia, n (%) 10 (23%) 6 (21%)
H-score B2 40 [10–90] 170 [43–263] <0.001
Corrected H-score B2 52 [10–275] 133 [46–375] 0.3
extra-APA B2-CNs (yes/no) 19/22 12/16 0.8
CYP11B1 expression (yes/no) 37/6 10/18 <0.001
Postural test (positive/negative) 9/23 7/12 0.4
Mutational status
WT, n (%) 16 (37%) 19 (68%) <0.001a
KCNJ5 mut, n (%) 25 (58%) 2 (7%) 0.19b
ATP1A1-ATP2B3-CACNA1D mut, n (%) 2 (5%) 7 (25%)
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity; extra-APA B2-CNs, extra-APA
CYP11B2-positive cell nests; ZF-like, zona fasciculata like; ZG-like, zona glomerulosa like.
a KCNJ5 vs WT and KCNJ5 vs ATP1A1-ATP2B3-CACNA1D.
b WT vs ATP1A1-ATP2B3-CACNA1D.
Table 2
Clinical and biochemical parameters, immunohistochemistry, genotyping and cellular composition according to the pres-
ence or absence of extra-APA CYP11B2-positive cell nests.
Parameter Extra-APA CYP11B2-positive cell nest P value
Present
(n = 31)
Absent
(n = 38)
Age (years) 48 ± 9 46 ± 13 0.4
Sex (M/F) 11/20 20/18 0.2
SBP (mmHg) 174 ± 24 171 ± 27 0.6
DBP (mmHg) 106 ± 12 104 ± 14 0.5
Plasma K+ (mEq/L) 2.9 ± 0.7 2.9 ± 0.7 0.9
PRA (ng/mL/h) 0.25 [0.20–0.50] 0.20 [0.20–0.30] 0.5
Plasma aldosterone (ng/dL) 44.8 [29–57.9] 51.9 [34.6–65.6] 0.2
Adenoma size (mm) 1.59 ± 0.7 1.68 ± 1.0 0.7
Adrenal CT scanning
Single nodule, n (%) 20 (64%) 35 (92%) 0.013
Multiple nodules, n (%) 3 (10%) 0 (0%)
No nodules, n (%) 8 (26%) 3 (8%)
Lateralization index 5.5 [4.4–11.8] 11.0 [5.6–21.3] 0.018
Contralateral suppression (yes/no) 20/10 31/4 0.039
Final diagnosis 0.5
Single nodule, n (%) 23 (74%) 31 (82%)
Multinodular hyperplasia, n (%) 8 (26%) 7 (18%)
H-score CYP11B2 80 [20–140] 60 [10–180] 0.7
Corrected H-score CYP11B2 86 [43–424] 110 [10–348] 0.7
Cellular composition (ZF-like/ZG-like) 19/12 22/16 0.810
CYP11B1 expression (yes/no) 20/11 25/13 0.556
Postural test (positive/negative) 8/14 8/19 0.761
Mutational status
WT, n (%) 13 (42%) 20 (53%) 0.627
KCNJ5 mut, n (%) 13 (42%) 14 (37%)
ATP1A1-ATP2B3-CACNA1D mut, n (%) 5 (16%) 4 (10%)
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity; ZF-like, zona fasciculata like;
ZG-like, zona glomerulosa like.
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expression of the two hydroxylases were inversely correlated (cor-
relation coefficient −0.395, p = 0.001). Overall, 47/69 (68%) of the
adrenal nodules identified by macroscopic examination displayed
positive immunostaining for CYP11B1. Forty-one out of 47 adrenal
nodules expressing CYP11B1 were larger than 1 cm and subclini-
cal cortisol hypercortisolism (defined as failure to suppress plasma
cortisol to less than 50 nmol/L after 1 mg-overnight dexametha-
sone) was excluded. APA patients expressing CYP11B1 were more
frequently females (p = 0.040), carryingmutations in KCNJ5 and com-
posed of ZF-like cells compared with APA patients not expressing
CYP11B1 (Fig. 1, panels E and F), as detailed in Table 4. Among clin-
ical and biochemical parameters, APA patients not expressing
CYP11B1 had higher SBP and lower potassium compared to pa-
tients expressing CYP11B1 in the adrenal nodule, despite neither
absolute aldosterone levels nor ARR differing between the two groups
(Table 4).
We also performed immunofluorescence staining in some of our
APA (Supplementary Fig. S2): most cells expressed either CYP11B2
(panel A) or CYP11B1 (panel B) and only a few cells co-expressed
both enzymes (panel C).
4. Discussion
Over the last few years great strides have been made in our un-
derstanding of the genetics and pathophysiology of sporadic and
familial PA. The activation of the calcium signaling pathway is crit-
ical for aldosterone secretion and represents the convergence point
of the different electrical and ionic alterations induced by the re-
cently reported somatic mutations in APAs (Azizan et al., 2013;
Beuschlein et al., 2013; Boulkroun et al., 2012; Choi et al., 2011;
Monticone et al., 2014a).
The final step in mineralocorticoid biosynthesis is catalyzed by
aldosterone synthase (encoded by CYP11B2), a mitochondrial enzyme
which shares 95% amino acid sequence identity with 11β-
hydroxylase (encoded by CYP11B1), that converts 11-deoxycortisol
to cortisol (Mulatero et al., 1998). Taking advantage of the re-
cently developed monoclonal antibodies (Gomez-Sanchez et al.,
2014), in the present study we investigated the relationship between
the presence of somatic mutations and the different cell histology
and immunohistochemical staining profiles for 11β-hydroxylase and
aldosterone synthase in a large cohort of 71 adrenal glands removed
for unilateral PA.
APA and BAH, the two most common forms of primary aldoste-
ronism, were originally considered distinct conditions. However, over
the last few years, this distinction began to blur and recent evi-
dence point toward a pathological continuum between APA and BAH
(Boulkroun et al., 2010; Omura et al., 2002). In fact, in the present
study, we observed that 23% of the assessed adrenals, preopera-
tively diagnosed as unilateral PA, showed multiple nodules and a
final diagnosis of multinodular hyperplasia was made.
In agreement with previous reports (Azizan et al., 2012, 2013),
our results suggest that KCNJ5 mutations can at least partially dif-
ferentiate a subpopulation of female APAs, which are composed of
large vacuolated cells and express CYP11B1 as a biomarker of the
zona fasciculata. In our cohort, the mean size of the adenomas did
not differ significantly according to the mutational status. However,
we observed a tendency toward smaller dimensions in CACNA1D-
mutant tumors compared to wild-type or KCNJ5-mutants, not
statistically significant due to the small sample size, highlighting
the need for AVS in subtype differentiation, in particular in those
patients with negative adrenal CT findings (Monticone et al., 2014c).
As outlined by Azizan et al. (2013), adenomas harboring ATP1A1,
Table 3
Clinical and biochemical parameters, immunohistochemistry, genotyping and cellular composition according to the level
(H-score) of CYP11B2 expression in the adrenal nodules.
Parameter CYP11B2 expression in adrenal nodules P value
H-score 0–160
(n = 55)
H-score 161–300
(n = 16)
Age (years) 48 ± 12 44 ± 12 0.4
Sex (M/F) 21/34 11/5 0.045
SBP (mmHg) 171 ± 26 176 ± 24 0.5
DBP (mmHg) 104 ± 13 109 ± 13 0.2
Plasma K+ (mEq/L) 2.9 ± 0.8 2.9 ± 0.5 0.9
PRA (ng/mL/h) 0.2 [0.2–0.3] 0.25 [0.2–0.52] 0.1
Plasma aldosterone (ng/dL) 45.3 [33.7–58.9] 51.4 [38.8–68.9] 0.2
Adenoma size (mm) 1.55 [1.0–2.42] 1.0 [1.0–1.47] 0.011
Adrenal CT scanning
Single nodule, n (%) 43 (78%) 13 (81%) 0.5
Multiple nodules, n (%) 4 (7%) 0 (0%)
No nodules, n (%) 8 (15%) 3 (19%)
Lateralization index 9.4 [5.0–17.0] 7.2 [4.3–14.6] 0.4
Contralateral suppression (yes/no) 41/10 12/4 0.7
Final diagnosis
Single nodule, n (%) 41 (74.5%) 14 (87.5%) 0.1
Multinodular hyperplasia, n (%) 14 (25.5%) 2 (12.5%)
CYP11B1 expression (yes/no) 42/13 5/11 0.002
Cellular composition (ZF-like/ZG-like) 41/14 2/14 <0.001
Extra-APA B2-CN (yes/no) 26/27 5/11 0.2
Postural test (positive/negative) 13/27 3/8 1.0
Mutational status
WT, n (%) 24 (44%) 11 (69%) 0.001a
KCNJ5 mut, n (%) 26 (47%) 1 (6%) 0.009b
ATP1A1-ATP2B3-CACNA1D mut, n (%) 5 (9%) 4 (25%) 0.46c
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity; Extra-APA B2-CN, CYP11B2-
positive cell nests; ZF-like, zona fasciculate like; ZG-like, zona glomerulosa like.
a KCNJ5 mut vs WT.
b 0.009 KCNJ5 mut vs ATP1A1-ATP2B3-CACNA1D mut.
c WT vs ATP1A1-ATP2B3-CACNA1D mut.
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ATP2B3 and CACNA1D mutations arise more frequently from zona
glomerulosa cells and display stronger positive immunostaining for
CYP11B2 compared to KCNJ5 mutant APAs. The so-called wild-
type tumors are probably a heterogeneous group of adenomas
carrying mutations in other so far unidentified genes. It is conceiv-
able that mutations of genes regulating ion exchange and in
particular calcium entry across the plasmamembrane of cells of the
zona glomerulosa, together with genes involved in the regulation
of cell growth and apoptosis, may be responsible for the APA for-
mation and regulation of aldosterone production in this group of
APA. We did not observe differences among clinical and biochem-
ical parameters between wild-type and mutated APAs (Williams
et al., 2014).
The prevalence of CT-undetectable APAs, which can be diag-
nosed only by AVS, is reported to be between 13% and 30% in
different series (Young et al., 2004). Ono et al. explored the status
of aldosterone production in small APAs, demonstrating that the im-
munoreactivity of CYP11B2was higher inmicroadenomas compared
to macroadenomas and the H-score of CYP11B2 inversely corre-
lated with the tumor area (Ono et al., 2014). Similarly, in our cohort,
CYP11B2 H-score displayed a negative correlation with adenoma
size and CYP11B1 expression and, after correction for tumor volume,
a positive correlation with plasma aldosterone levels and ARR, which
reflect the biochemical severity of the disease as reported before
(Nanba et al., 2013).
Interestingly, two samples showed negative CYP11B2
immunostaining in the main nodule and strong positive
immunostaining in a secondary small nodule, indicating that the
big nodulation detected by adrenal CT scanning (despite clear
lateralization at AVS) may not always be the source of aldosterone
overproduction in PA patients. This consideration, along with the
reported recurrence of PA after adrenal-sparing surgery (Ishidoya
et al., 2005), suggests that laparoscopic total adrenalectomy is pref-
erable over adenectomy.
It may be surprising the observation that some APAs did not show
detectable CYP11B2 immunostaining in the main or secondary
nodules; this has been found previously by other scientists: Dekkers
et al. (2014) found 9.6% APA that were CYP11B2-negative and no
other nodules expressing aldosterone-synthase; furthermore, in a
previous study Lenzini et al. (2007) reported 37.6% of APA with a
CYP11B2 gene expression inferior to normal adrenals. We per-
formed a real-time rt-PCR for CYP11B2 and in all APAs with negative
staining we could nonetheless demonstrate a detectable expres-
sion of CYP11B2. It is conceivable that in some cases CYP11B2
expression is not high enough to be detectable with immunohis-
tochemistry; however, a high number of cells producing small
quantity of aldosterone could result in a final increased aldoste-
rone production. After adrenalectomy, all these patients displayed
normalization of PRA, aldosterone, ARR and potassium levels, and
normalization or marked reduction of blood pressure levels.
We observed that multinodular hyperplasia is a frequent cause
of unilateral PA. This finding is in agreement with a recent study
by Iacobone et al. (2012) reporting a even higher prevalence of 65%.
It is conceivable that those groups that do not systematically use
AVS to discriminate between unilateral and bilateral PA may adre-
nalectomize only (or prevalently) patients with a single unilateral
nodule at CT scan, therefore having a relatively reduced probabil-
ity of multinodular hyperplasia at pathological examination. We did
Table 4
Clinical and biochemical parameters, immunohistochemistry, genotyping and cellular composition according to the pres-
ence or absence of CYP11B1 expression in the adrenal nodules.
Parameter CYP11B1 expression in adrenal nodules P value
Expressed
(n = 47)
Not expressed
(n = 24)
Age (years) 48 ± 10 44 ± 13 0.2
Sex (M/F) 17/30 15/9 0.045
SBP (mmHg) 167 ± 22 182 ± 29 0.018
DBP (mmHg) 103 ± 12 108 ± 14 0.1
Plasma K+ (mEq/L) 3.0 ± 0.6 2.6 ± 0.8 0.013
PRA (ng/mL/h) 0.2 [0.2–0.3] 0.2 [0.2–0.3] 0.3
Plasma aldosterone (ng/dL) 45.5 [33.9–58.0] 50.5 [31.3–72.8] 0.4
ARR 226 [115–359] 190 [104–415] 0.8
Adenoma size (mm) 1.8 ± 1.0 1.4 ± 0.6 0.06
Adrenal CT scanning 0.9
Single nodule, n (%) 34 (79%) 19 (79%)
Multiple nodules, n (%) 3 (6%) 1 (4%)
No nodules, n (%) 7 (15%) 4 (17%)
Lateralization index 7.6 [4.8–12.2] 14.2 [4.8–27.2] 0.059
Contralateral suppression (yes/no) 35/11 18/3 0.5
Final diagnosis 0.5
Single nodule, n (%) 35 (74.5%) 20 (83%)
Multinodular hyperplasia, n (%) 12 (25.5%) 4 (17%)
H-score CYP11B2 40 [10–120] 155 [45–262] 0.001
Corrected H-score CYP11B2 52 [10–274] 141 [51–375] 0.2
Cellular composition (ZF-like/ZG-like) 37/10 6/18 <0.001
Extra-APA B2-CN (yes/no) 20/25 11/13 1.0
Postural test (positive/negative) 11/25 5/10 0.7
Mutational status
WT, n (%) 21 (45%) 14 (58%) 0.047a
KCNJ5 mut, n (%) 23 (49%) 4 (17%) 0.0062b
ATP1A1-ATP2B3-CACNA1D mut, n (%) 3 (6%) 6 (25%) 0.14c
SBP, systolic blood pressure; DBP, diastolic blood pressure; PRA, plasma renin activity; extra-APA B2-CN, CYP11B2-
positive cell nests; ZF-like, zona fasciculata like; ZG-like, zona glomerulosa like.
a KCNJ5 mut vs WT.
b KCNJ5 mut vs ATP1A1-ATP2B3-CACNA1D mut.
c WT vs ATP1A1-ATP2B3-CACNA1D mut.
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not observe differences in the final biochemical or clinical outcome
between patients having multinodular hyperplasia or APA as shown
by others (Iacobone et al., 2012). No evidence of recurrent PA has
been observed in the follow-up.
Extra-APA B2-CNs have been identified both in normal adrenals
and in the context of the adjacent cortex to an APA as morpholog-
ically and immunohistochemically distinct structures expressing
CYP11B2, but not CYP11B1. Despite their functional significance re-
maining unclear, some authors have hypothesized that they might
give rise to an APA (Nishimoto et al., 2010). Overall, we observed
extra-APA B2-CNs in 45% of the removed adrenal glands. Adrenals
bearing extra-APA B2-CNs display more frequently multiple nodules
at adrenal CT scanning, lower LI and lower prevalence of contra-
lateral adrenal suppression compared to adrenal glands in which
extra-APA B2-CNs could not be identified. Despite the clinical sig-
nificance of extra-APA B2-CNs remaining poorly elucidated, it is
conceivable that in these cases PA was originally a bilateral disease
and subsequently, in the context of a multinodular adrenal gland,
an extra-APA B2-CN has given rise to an APA thus becoming dom-
inant (Gomez-Sanchez and Gomez-Sanchez, 2012).
Two subtypes of patients with APA have been identified, based
on different aldosterone response to up-right posture (AII-responsive
and AII-unresponsive APAs). The different cellular composition (pre-
dominance of ZF-like cells or ZG-like cells) has been suggested by
some authors to be responsible for this distinct biochemical be-
havior (Tunny et al., 1991), but was not confirmed in other series
(Fallo et al., 1998; Mune et al., 1993). In our cohort, there were no
significant differences between these two groups with respect to
the cellular composition, mutational status, clinical and biochem-
ical characteristics, CYP11B1 and CYP11B2 immunostaining.
5. Conclusions
In conclusion, our findings indicate that combination of
genotyping and immunohistochemistry improves the final histo-
pathological diagnosis between single nodule and multinodular
hyperplasia of the assessed adrenals. Most cases preoperatively clas-
sified as an APA are morphologically heterogeneous and the
identification of somatic mutations in KCNJ5, ATP1A1, ATP2B3 and
CACNA1D associated with the use of the recently developed mono-
clonal antibodies for aldosterone synthase and 11β-hydroxylase at
least partially accounts for this histopathological heterogeneity.
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